• Prioritizing target attributes beyond receptor density and expression to expand therapeutic reach
• Aligning target biology with alpha vs. beta emitter properties for more effective strategies
• Exploring novel opportunities in stromal markers like FAP and internalizing targets for durable responses

New Company for 2026